Company Email Format Management

Kyverna Therapeutics

Biotechnology Research 5980 Horton St 138 employees

Employees: 138
Contacts: 3
Emails: 3
Phones: 2

kyvernatx.com LinkedIn Crunchbase

Kyverna Therapeutics Overview

Headquarters: 5980 Horton St
Website: kyvernatx.com
Industry: Biotechnology Research
Employees: 138
Founded: 2018
Funding: 60.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

cell therapy autoimmune lupus multiple sclerosis systemic sclerosis scleroderma myasthenia gravis CAR T-cell stiff-person syndrome

About Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Kyverna Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 2; 50.0% coverage

Kyverna Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
John Farris	Vice President, Head of Gxp Quality	San Francisco Bay Area, United States	Email
Maria Avina		Whittier, California, United States	Email Phone
George Azar	Talent Acquisition Consultant @ Kyverna Therapeutics - Acir, Recruiter Certificate	Los Angeles, California, United States	Email Phone
Sarah L.		South San Francisco, California, United States	View